Talaris Therapeutics to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
BOSTON and LOUISVILLE, Ky., Jan. 4, 2022 – Talaris Therapeutics (Nasdaq: TALS), a late-clinical stage cell therapy company, announced that CEO Scott Requadt will present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BOSTON and LOUISVILLE, Ky., Jan. 4, 2022 – Talaris Therapeutics (Nasdaq: TALS), a late-clinical stage cell therapy company, announced that CEO Scott Requadt will present at the H.C. Wainwright BioConnect 2022 Virtual Conference from January 10-13, 2022. The pre-recorded presentation will be available starting at 7:00 AM ET on January 10 on Talaris' website, where it will remain archived for 90 days. Talaris focuses on developing therapies aimed at revolutionizing treatment for solid organ transplantation and severe immune and blood disorders.
Details
News Market Reaction – TALS
The recorded move for TALS in the trading session of this news was -3.56%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON and LOUISVILLE, Ky., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at the H.C. Wainwright BioConnect 2022 Virtual Conference being held January 10-13, 2022.
A webcast of the pre-recorded presentation will be made available the morning of the conference starting at 7:00 AM ET on Monday, January 10th, and can be accessed by visiting the investors section of the Talaris website at www.talaristx.com. After the live webcast, the event will remain archived on the Talaris website for 90 days.
About Talaris Therapeutics
Talaris Therapeutics, Inc. is a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders. Talaris maintains corporate offices in Boston, MA, its cell processing facility in Louisville, KY, and additional research operations in Houston, TX.
Media Contact
Lisa Raffensperger
Ten Bridge Communications
lisa@tenbridgecommunications.com
(617) 903-8783
Investor Contact
Chris Brinzey
Westwicke, an ICR Company
chris.brinzey@westwicke.com
(339) 970-2843
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.